

Dr. Silvia Riondino Biosketch

Silvia Riondino received her MD in 1991. Specialist in Clinical Pathology (1996), she obtained a PhD in Experimental Medicine (2001) and a post-PhD in 2003, at the "Sapienza" University of Rome. From 1985 to 2008 she joined the Laboratory of Platelet Patophysiology of the Department of Experimental Medicine and Pathology of the "Sapienza" University of Rome, where she carried out independent research projects. From 2008 to 2013 she has been the referent of the hematology section of the Department of Laboratory Medicine and Advanced Biotechnologies, of the IRCCS San Raffaele Pisana, Rome.

Since 2013, Dr. Riondino is independent researcher at the IRCCS San Raffaele Pisana Research Center and collaborates with the Interinstitutional Multidisciplinary Biobank (BioBIM). She is also consultant for the Clinical Trial Unit of the Medical Oncology Operative Unit at the University Hospital "Tor Vergata" of Rome and Contract Professor at the School of Specialization in Medical Oncology, where she holds a course titled "Clinical Trial design: the science of Biobanking". Since 2018 Dr. Riondino is Teaching Assistant in Oncology at the University of Rome Tor Vergata, for the Degrees in Physiotherapy and Biomedical Laboratory Techniques, and since 2019 she is Contract Professor of Oncology at the Catholic University "Our Lady of Good Counsel" in Tirane.

Dr. Riondino's main fields of interest, have been the study of: 1) biochemical pathways of platelet pathology and physiology; 2) pathophysiological mechanisms responsible for the thrombophilic state associated with chronic degenerative diseases (chronic obstructive pulmonary disease, cardiovascular diseases), with cardiovascular risk factors (diabetes, hypercholesterolemia, hyperhomocysteinemia, obesity) and certain neoplastic conditions such as cancer of the colorectal tract and lung; 3) mechanisms involved in the pathogenesis of many chronic disabling diseases, with particular attention to the interactions between inflammation, angiogenesis and hemostasis, to identify biomarkers, "emerging" risk factors and possible determinants of outcome in patients with chronic disabling diseases both in primary prevention, and during the therapeutic/rehabilitation phases of such patients; 4) "quality criteria" to be applied to biological samples for the Biological Bank BioBIM (IRCCS San Raffaele) and PTV-Bio.Ca.Re (University Hospital "Tor Vergata") projects.

The scientific activity described above has resulted, so far (July 2019), in the publication of 86 full papers in national and international journals, with an H-index of 21 chapters in books and 67 Abstracts in national and international congresses.

Rome, 12/07/2019